Racial disparities in survival and stage at diagnosis among adolescent and young adult patients with cancer.

Authors

Kekoa Taparra

Kekoa A. Taparra

Stanford Cancer Institute, Palo Alto, CA

Kekoa A. Taparra , Kāʻeo Kekumano , Ryan Benevente , Megan Y. Gimmen , Connon Kinslow , Curtiland Deville , Erqi L. Pollom

Organizations

Stanford Cancer Institute, Palo Alto, CA, Harvard University, Cambridge, MA, Harvard Medical School, Boston, MA, Columbia University Medical Center, New York, NY, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Research Funding

Other
Stanford Cancer Institute – Women Cancer Center’s Innovation Award; Stanford Cancer Institute – SCI Fellowship Award; Stanford Cancer Institute - Cancer Innovation Award

Background: Adolescent and young adult (AYA) patients (15-39 years) are an underrecognized population with high risk of select malignancies. Compared to pediatric and adult patients, AYA patients have not achieved improvements in cancer survival. No studies have evaluated overall survival (OS) and stage at diagnosis among all 5 federally recognized races in the US. Here we aim to investigate OS and stage at diagnosis among AYA patients by race. Methods: A retrospective cohort study of AYA patients diagnosed between 2004-2017 was conducted with the National Cancer Database. Patients with the 10 deadliest AYA cancers with at least 6 months of follow-up were included. Primary endpoints were OS (time from diagnosis to death) and late stage at diagnosis (stage III/IV or Grade III/IV for central nervous system [CNS] cancer). Kaplan-Meier estimates and log-rank tests assessed OS. OS and late stage were evaluated by race using multivariable Cox proportional hazard (adjusted hazard ratio [aHR]) and logistic (adjusted odds ratio [aOR]) regressions, respectively, with 95% confidence intervals (95%CI). All regressions were adjusted for sociodemographic and cancer characteristics. Results: 291,899 AYA patients were included: 64% female, 65% stage I/II, and 62 month median follow-up. Cancer sites included 27% breast, 16% lymphoma, 13% melanoma, 11% testis, 9% CNS, 7% colorectal, 7% cervix, 5% sarcoma, 3% ovary, and 2% lung. Race included 82.3% Non-Hispanic White (NHW), 14.0% Black, 2.9% Asian, 0.5% American Indian and Alaska Native (AIAN), and 0.3% Native Hawaiian and other Pacific Islander (NHPI). OS differed for all cancers by race (p<.0001), except for lung (p=.008), CNS (p=.32), and ovary (p=.28). OS was significantly inferior for NHPI, Black, and AIAN but superior for Asian, versus NHW (Table). NHPI had inferior OS (aHR, 95%CI) for melanoma (4.5, 2.0-10.0), colorectal (1.8, 1.3-2.4), lymphoma (1.7, 1.1-2.1), and cervix (1.6, .1-2.4) cancers. Black patients had inferior OS for melanoma (1.6, 1.2-2.2), lymphoma (1.5, 1.4-1.6), and breast (1.4, 1.3-1.4) cancers. Asian patients had superior OS for breast (0.7, 0.7-0.8) and lung (0.7, 0.6-0.9) but inferior survival for testis (1.9, 1.3-2.9) cancers. AIAN patients had inferior OS for colorectal (1.4, 1.0-1.9). Late stage at diagnosis was higher for NHPI, Black, and Asian patients, compared to NHW patients (Table). Conclusions: Both NHPI and Black AYA patients with cancer have higher risk of death and late stage disease at diagnosis, compared to NHW patients. Our data reveal racial disparities among Indigenous AYA patients masked by prior data omission.

RaceaHR95%CIPaOR95%CIP
White1.00Ref1.00Ref
AIAN1.15(1.02-1.30)0.0211.09(0.96-1.22)0.177
Asian0.90(0.85-0.95)<0.0011.20(1.14-1.26)<0.001
Black1.22(1.19-1.26)<0.0011.40(1.36-1.43)<0.001
NHPI1.25(1.09-1.44)0.0021.34(1.16-1.55)<0.001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6615)

DOI

10.1200/JCO.2023.41.16_suppl.6615

Abstract #

6615

Poster Bd #

107

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Use of novel cancer staging model to analyze healthcare costs of commercially insured patients with colorectal cancer.

First Author: Rebecca Smith

First Author: Alexandra Gangi

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Comparative genomic analysis to identify a signature of sporadic colorectal cancer development in young adults.

First Author: Abedalrhman Alkhateeb

First Author: Elizabeth Rodriguez